ALNY Annual CAPEX
$62.21 M
-$9.85 M-13.67%
31 December 2023
Summary:
As of January 20, 2025, ALNY annual capital expenditures is $62.21 million, with the most recent change of -$9.85 million (-13.67%) on December 31, 2023. During the last 3 years, it has fallen by -$8.15 million (-11.58%). ALNY annual CAPEX is now -55.61% below its all-time high of $140.16 million, reached on December 31, 2019.ALNY CAPEX Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ALNY Quarterly CAPEX
$4.19 M
-$3.83 M-47.72%
30 September 2024
Summary:
As of January 20, 2025, ALNY quarterly capital expenditures is $4.19 million, with the most recent change of -$3.83 million (-47.72%) on September 30, 2024. Over the past year, it has dropped by -$12.90 million (-75.47%). ALNY quarterly CAPEX is now -90.77% below its all-time high of $45.41 million, reached on September 30, 2018.ALNY Quarterly CAPEX Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ALNY TTM CAPEX
$40.49 M
-$12.90 M-24.16%
30 September 2024
Summary:
As of January 20, 2025, ALNY TTM capital expenditures is $40.49 million, with the most recent change of -$12.90 million (-24.16%) on September 30, 2024. Over the past year, it has dropped by -$28.05 million (-40.92%). ALNY TTM CAPEX is now -72.95% below its all-time high of $149.68 million, reached on March 31, 2019.ALNY TTM CAPEX Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ALNY CAPEX Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -13.7% | -75.5% | -40.9% |
| 3 y3 years | -11.6% | -75.5% | -40.9% |
| 5 y5 years | -51.0% | -75.5% | -40.9% |
ALNY CAPEX High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -18.5% | at low | -80.8% | at low | -50.5% | at low |
| 5 y | 5-year | -55.6% | at low | -89.2% | at low | -71.1% | at low |
| alltime | all time | -55.6% | +4718.8% | -90.8% | >+9999.0% | -73.0% | +3036.5% |
Alnylam Pharmaceuticals CAPEX History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $4.19 M(-47.7%) | $40.49 M(-24.2%) |
| June 2024 | - | $8.02 M(-38.2%) | $53.39 M(-12.9%) |
| Mar 2024 | - | $12.97 M(-15.3%) | $61.29 M(-1.5%) |
| Dec 2023 | $62.21 M(-13.7%) | $15.31 M(-10.4%) | $62.21 M(-9.2%) |
| Sept 2023 | - | $17.09 M(+7.4%) | $68.54 M(+0.9%) |
| June 2023 | - | $15.92 M(+14.6%) | $67.95 M(-0.2%) |
| Mar 2023 | - | $13.89 M(-35.8%) | $68.09 M(-5.5%) |
| Dec 2022 | $72.06 M(-5.6%) | $21.64 M(+31.0%) | $72.06 M(-0.3%) |
| Sept 2022 | - | $16.51 M(+2.8%) | $72.31 M(-11.7%) |
| June 2022 | - | $16.05 M(-10.1%) | $81.86 M(+6.2%) |
| Mar 2022 | - | $17.86 M(-18.4%) | $77.05 M(+0.9%) |
| Dec 2021 | $76.37 M(+8.5%) | $21.89 M(-16.0%) | $76.37 M(+0.3%) |
| Sept 2021 | - | $26.06 M(+131.7%) | $76.15 M(+21.8%) |
| June 2021 | - | $11.25 M(-34.5%) | $62.51 M(-8.0%) |
| Mar 2021 | - | $17.18 M(-20.7%) | $67.92 M(-3.5%) |
| Dec 2020 | $70.36 M(-49.8%) | $21.67 M(+74.5%) | $70.36 M(-19.6%) |
| Sept 2020 | - | $12.42 M(-25.5%) | $87.50 M(-21.3%) |
| June 2020 | - | $16.66 M(-15.1%) | $111.14 M(-4.0%) |
| Mar 2020 | - | $19.62 M(-49.4%) | $115.72 M(-17.4%) |
| Dec 2019 | $140.16 M(+10.5%) | $38.80 M(+7.6%) | $140.16 M(+0.9%) |
| Sept 2019 | - | $36.06 M(+69.7%) | $138.86 M(-6.3%) |
| June 2019 | - | $21.24 M(-51.8%) | $148.22 M(-1.0%) |
| Mar 2019 | - | $44.05 M(+17.4%) | $149.68 M(+18.0%) |
| Dec 2018 | $126.89 M(+21.8%) | $37.51 M(-17.4%) | $126.89 M(+15.2%) |
| Sept 2018 | - | $45.41 M(+100.0%) | $110.10 M(+21.8%) |
| June 2018 | - | $22.71 M(+6.8%) | $90.37 M(+1.2%) |
| Mar 2018 | - | $21.26 M(+2.6%) | $89.31 M(-14.3%) |
| Dec 2017 | $104.21 M(+61.4%) | $20.73 M(-19.3%) | $104.21 M(+0.8%) |
| Sept 2017 | - | $25.68 M(+18.6%) | $103.36 M(+5.5%) |
| June 2017 | - | $21.65 M(-40.1%) | $97.98 M(+10.2%) |
| Mar 2017 | - | $36.15 M(+81.9%) | $88.89 M(+37.7%) |
| Dec 2016 | $64.56 M(+398.5%) | $19.88 M(-2.1%) | $64.56 M(+35.1%) |
| Sept 2016 | - | $20.30 M(+61.6%) | $47.78 M(+40.7%) |
| June 2016 | - | $12.56 M(+6.3%) | $33.96 M(+49.9%) |
| Mar 2016 | - | $11.82 M(+281.3%) | $22.66 M(+74.9%) |
| Dec 2015 | $12.95 M(+44.5%) | $3.10 M(-52.2%) | $12.95 M(-3.2%) |
| Sept 2015 | - | $6.48 M(+412.4%) | $13.38 M(+32.5%) |
| June 2015 | - | $1.26 M(-40.1%) | $10.10 M(-5.5%) |
| Mar 2015 | - | $2.11 M(-40.2%) | $10.68 M(+19.2%) |
| Dec 2014 | $8.96 M | $3.53 M(+10.4%) | $8.96 M(+41.9%) |
| Sept 2014 | - | $3.19 M(+72.5%) | $6.31 M(+55.2%) |
| June 2014 | - | $1.85 M(+377.3%) | $4.07 M(+56.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2014 | - | $388.00 K(-55.8%) | $2.60 M(-35.2%) |
| Dec 2013 | $4.01 M(-52.0%) | $878.00 K(-7.6%) | $4.01 M(+5.0%) |
| Sept 2013 | - | $950.00 K(+150.7%) | $3.81 M(-55.6%) |
| June 2013 | - | $379.00 K(-78.9%) | $8.59 M(-13.1%) |
| Mar 2013 | - | $1.80 M(+162.2%) | $9.88 M(+18.4%) |
| Dec 2012 | $8.35 M(+546.6%) | $686.00 K(-88.0%) | $8.35 M(+2.0%) |
| Sept 2012 | - | $5.73 M(+243.1%) | $8.19 M(+200.7%) |
| June 2012 | - | $1.67 M(+535.0%) | $2.72 M(+78.4%) |
| Mar 2012 | - | $263.00 K(-49.8%) | $1.53 M(+18.2%) |
| Dec 2011 | $1.29 M(-72.7%) | $524.00 K(+97.7%) | $1.29 M(-32.2%) |
| Sept 2011 | - | $265.00 K(-44.1%) | $1.91 M(-29.6%) |
| June 2011 | - | $474.00 K(+1592.9%) | $2.71 M(-26.1%) |
| Mar 2011 | - | $28.00 K(-97.5%) | $3.66 M(-22.6%) |
| Dec 2010 | $4.73 M(-4.4%) | $1.14 M(+6.7%) | $4.73 M(-2.6%) |
| Sept 2010 | - | $1.07 M(-25.4%) | $4.86 M(+7.3%) |
| June 2010 | - | $1.43 M(+30.4%) | $4.53 M(+8.8%) |
| Mar 2010 | - | $1.10 M(-13.3%) | $4.16 M(-15.9%) |
| Dec 2009 | $4.95 M(-54.0%) | $1.26 M(+71.6%) | $4.95 M(-0.4%) |
| Sept 2009 | - | $737.00 K(-30.6%) | $4.97 M(-23.7%) |
| June 2009 | - | $1.06 M(-43.7%) | $6.51 M(-32.9%) |
| Mar 2009 | - | $1.89 M(+46.8%) | $9.70 M(-9.8%) |
| Dec 2008 | $10.76 M(+38.2%) | $1.28 M(-43.7%) | $10.76 M(-21.5%) |
| Sept 2008 | - | $2.28 M(-46.3%) | $13.71 M(+13.0%) |
| June 2008 | - | $4.25 M(+44.4%) | $12.14 M(+29.4%) |
| Mar 2008 | - | $2.94 M(-30.4%) | $9.38 M(+20.4%) |
| Dec 2007 | $7.79 M(+56.2%) | $4.23 M(+500.6%) | $7.79 M(+102.5%) |
| Sept 2007 | - | $705.00 K(-52.8%) | $3.85 M(-1.1%) |
| June 2007 | - | $1.50 M(+10.4%) | $3.89 M(-20.0%) |
| Mar 2007 | - | $1.35 M(+365.3%) | $4.86 M(-2.6%) |
| Dec 2006 | $4.99 M(+156.1%) | $291.00 K(-61.0%) | $4.99 M(-5.8%) |
| Sept 2006 | - | $746.00 K(-69.7%) | $5.29 M(+7.6%) |
| June 2006 | - | $2.46 M(+66.1%) | $4.92 M(+74.3%) |
| Mar 2006 | - | $1.48 M(+147.3%) | $2.82 M(+45.0%) |
| Dec 2005 | $1.95 M(-78.4%) | $600.00 K(+61.3%) | $1.95 M(-28.8%) |
| Sept 2005 | - | $372.00 K(+1.1%) | $2.74 M(-22.8%) |
| June 2005 | - | $368.00 K(-39.4%) | $3.54 M(-52.6%) |
| Mar 2005 | - | $607.00 K(-56.3%) | $7.47 M(-17.0%) |
| Dec 2004 | $9.01 M(+188.7%) | $1.39 M(+17.8%) | $9.01 M(+18.2%) |
| Sept 2004 | - | $1.18 M(-72.6%) | $7.62 M(+18.3%) |
| June 2004 | - | $4.30 M(+101.0%) | $6.44 M(+201.0%) |
| Mar 2004 | - | $2.14 M | $2.14 M |
| Dec 2003 | $3.12 M | - | - |
FAQ
- What is Alnylam Pharmaceuticals annual capital expenditures?
- What is the all time high annual CAPEX for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals annual CAPEX year-on-year change?
- What is Alnylam Pharmaceuticals quarterly capital expenditures?
- What is the all time high quarterly CAPEX for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals quarterly CAPEX year-on-year change?
- What is Alnylam Pharmaceuticals TTM capital expenditures?
- What is the all time high TTM CAPEX for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals TTM CAPEX year-on-year change?
What is Alnylam Pharmaceuticals annual capital expenditures?
The current annual CAPEX of ALNY is $62.21 M
What is the all time high annual CAPEX for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high annual capital expenditures is $140.16 M
What is Alnylam Pharmaceuticals annual CAPEX year-on-year change?
Over the past year, ALNY annual capital expenditures has changed by -$9.85 M (-13.67%)
What is Alnylam Pharmaceuticals quarterly capital expenditures?
The current quarterly CAPEX of ALNY is $4.19 M
What is the all time high quarterly CAPEX for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high quarterly capital expenditures is $45.41 M
What is Alnylam Pharmaceuticals quarterly CAPEX year-on-year change?
Over the past year, ALNY quarterly capital expenditures has changed by -$12.90 M (-75.47%)
What is Alnylam Pharmaceuticals TTM capital expenditures?
The current TTM CAPEX of ALNY is $40.49 M
What is the all time high TTM CAPEX for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high TTM capital expenditures is $149.68 M
What is Alnylam Pharmaceuticals TTM CAPEX year-on-year change?
Over the past year, ALNY TTM capital expenditures has changed by -$28.05 M (-40.92%)